Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 10/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29306874 | 0.79 | ERN1 (0.42) | ERN1MAPK1RAB9ALMNACYP3A4 | |
| SCHEMBL10548337 | 0.78 | LMNA (0.40) | ERN1MAPK1RAB9ALMNACYP3A4 | |
| SCHEMBL10548331 | 0.72 | ERN1 (0.40) | ERN1MAPK1RAB9ALMNACYP3A4 | |
| SCHEMBL9383271 | 0.70 | ERN1 (0.49) | ERN1MAPK1RAB9ALMNACYP3A4 | |
| SCHEMBL9191402 | 0.70 | LMNA (0.42) | ERN1MAPK1RAB9ALMNACYP3A4 | |
| SCHEMBL8924794 | 0.70 | LMNA (0.42) | ERN1MAPK1RAB9ALMNACYP3A4 | |
| SCHEMBL597800 | 0.69 | LMNA (0.45) | ERN1MAPK1RAB9ALMNACYP3A4 | |
| SCHEMBL6686807 | 0.68 | ERN1 (0.51) | ERN1MAPK1RAB9ALMNACYP3A4 | |
| SCHEMBL4195614 | 0.68 | LMNA (0.46) | ERN1MAPK1RAB9ALMNACYP3A4 | |
| SCHEMBL5670115 | 0.67 | ADRA1D (0.41) | MAPK1RAB9ALMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1476427-A4 | PEPTIDE BETA-STRAND MIMICS BASED ON 1,2-DIHYDRO-3(6H)-PYRIDINONE | UNIV CALIFORNIA (US) | 2006-04-19 | — | — | EP | disclosed |
| US-20050043538-A1 | Peptide beta-strand mimics based on 1,2-dihydro-3(6H)-pyridinone | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-02-24 | — | — | US | disclosed |
| EP-1476427-A2 | PEPTIDE BETA-STRAND MIMICS BASED ON 1,2-DIHYDRO-3(6H)-PYRIDINONE | The Regents of the University of California (US) | 2004-11-17 | — | — | EP | disclosed |
| US-20030073721-A1 | Peptide beta-strand mimics based on 1,2-dihydro-3(6H)-pyridinone | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION (US) | 2003-04-17 | — | — | US | disclosed |
| WO-2002099045-A2 | PEPTIDE BETA-STRAND MIMICS BASED ON 1,2-DIHYDRO-3(6H)-PYRIDINONE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073721-A1 | Peptide beta-strand mimics based on 1,2-dihydro-3(6H)-pyridinone | IAPP, VIP, APP | ERN1 3229/4885MAPK1 3733/4885RAB9A 2338/4885 |
| US-20050043538-A1 | Peptide beta-strand mimics based on 1,2-dihydro-3(6H)-pyridinone | IAPP, APP, VIP | ERN1 2789/4885MAPK1 3524/4885RAB9A 2372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.